Health-Holland

Source: EFPIA, Patient W.A.I.T. Indicator 2017 Average time between marketing authorisation and patient access 1,000 800 600 400 200 0- Average delay (days) For most countries patient access equates to granting of access to the reimbursement list, except for hospital products in DK, FI, NO, SE where some products are not covered by the general reimbursement scheme and so the zero-delay is artificially declining the median and average. In France, some innovative products without competitors can be made available prior to market authorisation under the system of Temporary Authorisations. As these are not taken into account in the analysis, the average for France is higher than in reality. Serbia 979 Poland 632 Portugal 606 Lithuania 563 Bulgaria 535 France 500 Slovenia 490 Croatia 479 Latvia 467 Italy 438 Belgium 411 Ireland 396 Slovakia 379 Spain 329 Austria 329 Norway 291 Sweden 281 Denmark 269 Netherlands 228 Switzerland 123 UK 111 Germany 106 Estonia 436 52